Long-term data reveals cribriform-positive status drives metastatic risk in prostate cancer patientsA hidden marker in prostate cancer slides predicts deadly outcomes after surgery

This secondary analysis of the ProtecT randomized controlled trial examined long-term outcomes in men with clinically localized prostate cancer who underwent radical prostatectomy. The study population included 1,643 participants enrolled between 1999 and 2009, with pathology slides centrally reviewed to classify disease as cribriform-positive or cribriform-negative. The primary objective was to determine if cribriform status predicted progression to metastatic disease or death from prostate cancer over a fifteen-year follow-up period. Results demonstrated a stark divergence in outcomes based on this histological feature, fundamentally altering the risk stratification landscape for post-prostatectomy patients.

The most striking finding was that all twenty-one events of metastasis or death from prostate cancer occurred exclusively within the cribriform-positive group. Conversely, the cribriform-negative group experienced zero such events over the entire fifteen-year observation window. This absolute difference highlights cribriform-positive status as a powerful discriminator of aggressive disease biology. The data suggests that the presence of cribriform architecture is not merely a morphological curiosity but a critical prognostic indicator that may necessitate a shift in clinical management strategies for affected individuals.

Further stratification revealed that risk was heavily concentrated in specific subgroups within the cribriform-positive cohort. Patients presenting with pT3b stage disease and/or Gleason score three or higher exhibited a twenty-seven percent risk of adverse outcomes. In contrast, those with cribriform-positive disease but lower pathological features, specifically Gleason score two and pT3a stage or less, demonstrated a significantly lower three percent event rate. This nuance underscores the importance of integrating cribriform status with traditional pathological staging and grading to refine risk assessment.

Multivariable Cox proportional hazards regression models confirmed the independent predictive value of these factors. For cribriform-positive patients with pT3b stage disease, advanced pathological stage emerged as an independent predictor of adverse outcomes, with a hazard ratio of 8.19. Similarly, Gleason score three disease in this high-risk group was an independent predictor with a hazard ratio of 5.12. These statistical associations, derived from robust regression analyses, provide quantitative evidence supporting the clinical relevance of cribriform status beyond standard staging parameters.

The study limitations include its retrospective nature, as it analyzed data from an existing trial rather than a prospective interventional design. However, the rigorous central review of pathology slides and the large sample size lend credibility to the findings. The absence of reported adverse events or discontinuations is consistent with the observational nature of the analysis, which focused on long-term survival and progression rather than treatment toxicity. These results do not claim causality but rather establish a strong association between cribriform status and clinical outcomes.

For clinicians, this analysis identifies a distinct target population for future adjuvant therapy trials. Patients with cribriform-positive disease, particularly those with higher stage or grade, may benefit from more aggressive surveillance or early intervention. Conversely, the low event rate in cribriform-positive patients with favorable pathological features supports management de-escalation for the majority of radical prostatectomy patients. This distinction allows for more personalized care, avoiding overtreatment in low-risk individuals while ensuring adequate protection for those harboring aggressive disease biology.